B2C2

Companies

B2C2 is a London-based institutional Bitcoin and digital asset market maker founded in 2015, widely recognized as one of the most sophisticated electronic trading firms in the crypto space. The firm provides around-the-clock liquidity across spot, derivatives, and structured products to exchanges, banks, brokerages, and institutional investors. B2C2 was acquired by Japanese financial group SBI Holdings in 2020, giving it significant balance sheet capacity and regulatory standing. The firm is known for its technology-first approach and algorithmic market making capabilities.

Details

Ceo: Thomas Restout
Public: No
Sector: trading_desk
Known For: Institutional Bitcoin market maker; acquired by SBI Group 2020; 24/7 liquidity for crypto trading
Company Type: OTC Market Maker / Prime Brokerage
Founded Year: 2015
Headquarters: London, UK
Parent Company: SBI Holdings
Bitcoin Strategy: Institutional crypto prime brokerage providing OTC trading and liquidity services in Bitcoin to banks, hedge funds, and asset managers.
Bitcoin Holdings Note: Private company — holds operational BTC inventory as market maker. No public disclosure. Subsidiary of SBI Holdings.

Links

twitter

More Companies

Strategy (formerly MicroStrategy)

Strategy (Nasdaq: MSTR), formerly MicroStrategy, is the world's largest corporate Bitcoin holder. Founded by Michael Saylor, the company rebranded in 2025 to reflect its identity as a Bitcoin treasury company. It holds over 500,000 BTC accumulated through equity and debt financing, pioneering the corporate Bitcoin standard that inspired hundreds of companies worldwide.

ACINQ

ACINQ is a French Bitcoin infrastructure company and the developer of Eclair, one of the three major Lightning Network implementations. Founded in 2014, ACINQ builds Phoenix Wallet (a non-custodial Lightning wallet) and operates the ACINQ Lightning node, one of the most well-connected nodes on the Lightning Network.

Acurx Pharmaceuticals

Acurx Pharmaceuticals (NASDAQ: ACXP) is a US biopharmaceutical company that made headlines in November 2021 by adopting Bitcoin as its primary treasury reserve asset — one of the first pharmaceutical companies to do so. The company approved purchasing $1 million in Bitcoin and has continued to hold BTC alongside its drug development pipeline focused on antibiotics. Notable for crossing industry boundaries to embrace the Bitcoin standard.